Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

NCT03463044 PHASE1 COMPLETED Results posted

This was a single center, randomized, placebo-controlled study with a sequential i.v. dose escalation cohorts design, to assess safety, tolerability and pharmacokinetics of MOTREM (nangibotide) in healthy volunteers

Details

Lead sponsor	Inotrem
Phase	PHASE1
Status	COMPLETED
Enrolment	27
Start date	Fri Apr 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy Subjects

Interventions

• nangibotide
• Placebo

Countries

United Kingdom